Search
Close this search box.

ASTHMA

cliinical_trials_cystic_fibrosis

ELIGIBILITY & REQUIREMENTS

  • Aged 18 years and older.
  • Diagnosis of asthma.
  • Already on mepolizumab or benralizumab.

WHAT'S INVOLVED

  • The trial will run for up to 15 months.
  • During this period you will be required to attend up to 18 visits to the Institute for Respiratory Health at QEII Medical Centre in Nedlands.

STUDY OUTLINE

This study is a Phase 3 clinical trial which aims to evaluate a potential new medicine for severe asthma and is not yet approved to treat patients with asthma.

GSK3511294 (also known as the study drug) is a type of medicine called a monoclonal antibody that is made in the laboratory. It works by blocking a specific protein in the body called interleukin-5 which is involved in the severity of asthma and inflammation of the lungs.

The study drug works the same way as three already approved asthma medications: mepolizumab, reslizumab, and benralizumab. These medications are taken every 4 to 8 weeks. However, it is hoped that the effect of the study drug will last over a longer period of time (once every 26 weeks).

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at clinicaltrials@resphealth.uwa.edu.au or phone 6151 0888.

PRINCIPAL INVESTIGATOR

Dr John Blakey

LOCATION

Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)

REGISTER YOUR INTEREST TODAY

* indicates required
Scroll to Top